Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Dec 06, 2021 10:49am
82 Views
Post# 34202060

RE:Biggest annual Sell Side event

RE:Biggest annual Sell Side eventLike many of the smaller companies that don't get a direct invite from JPM to participate, TH has historically gone to the conference and hung around the perimeter of it, meeting with bankers, analysts, buyside PM's and other companies. I would be surprised if they were not doing the same this year. If I recall correctly, the meeting they had with Taimed there helped get the Trogarzo deal done, so who knows what might come up on the NASH or cancer front this year. 

Maybe they can get LSA to update the corporate presentation for them! The fact tht it has not been updated may mean some important news is coming out soon and they are awaiting that before doing a major overhaul. The early and larger tha normal options grant suggests something like that may be happening too.

Wino115 wrote:

JPMorgan Healthcare Conf coming up and doesn't appear THTX is bothering with it again. Even if not invited, many companies flock around it and offer up call times.  I get the sense Life Sci Advisors is finished with their "rebranding". It was just for web, some films, the presentation and speech to go along with it.  Bit surprised their analyst didn't pick it up, but maybe using a different firm for the NASH partner search ticked them off.  


I would still score the LSA consulting ideas as very helpful and professional.  THTX management know speak about the opportunities and science in the right way, knowing what to emphasize and the buzz words that resonate in investors heads.  



<< Previous
Bullboard Posts
Next >>